Who sold Abus stock in the last quarter?
On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. In particular, Arbutus took ...
Should investors worry about Arbutus Biopharma (Abus) stock?
Find the latest Arbutus Biopharma Corporation (ABUS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Is there a massive purchase of shares by executives suspicious?
· Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABUS shares have decreased by 23.3% and is now trading at $1.98. View which stocks have been most impacted by COVID-19.
See more
· This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.43 between high …
Is Abus stock a good investment?
ABUS has a Quality Grade of D, ranking ahead of 23.96% of graded US stocks. ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
What does Arbutus Biopharma do?
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company's current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses.
Who owns Arbutus?
General Public Ownership The general public -- including retail investors -- own 51% of Arbutus Biopharma. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
Who is the owner of Arbutus Biopharma?
William (Bill) Collier - President and Chief Executive Officer - Arbutus Biopharma Corporation | LinkedIn.
Is Arbutus Biopharma a buy right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy rat...
How has Arbutus Biopharma's stock price been impacted by Coronavirus?
Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organizat...
When is Arbutus Biopharma's next earnings date?
Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Arbu...
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma Co. (NASDAQ:ABUS) issued its earnings results on Thursday, March, 3rd. The biopharmaceutical company reported ($0.15) EPS for the...
What price target have analysts set for ABUS?
4 brokerages have issued 1-year target prices for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $9.00. On average, they expect Arb...
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the following people: William H. Collier , President, Chief Executive Officer & Director David C. Ha...
What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?
6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com . Mark J. Murray has an approval rating of 22% among Arbutus Biopharm...
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include ChemoCentryx (CCXI) , Prothena (PRTA) , Prometheus Biosciences (RXDX) , 23andMe (M...
What other stocks do shareholders of Arbutus Biopharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Syst...
What is Arbutus ranked for in 2021?
Is Arbutus a patent holder?
Hedge Fund News published 14 November 2021. Arbutus ranked 4 for AB-729 and Patent dispute with Moderna over LNP. Positive article for ABUS. GL ALL
Does Moderna use Arbutus?
While Arbutus is the patent holder, this patent has been licensed to Genevant. The '069 Patent was included in this license agreement between Genevant and Arbutus. Arbutus is gratified by the recent decision of the PTAB, upholding the validity of one of the patents protecting Arbutus' LNP technology that Arbutus licensed to Genevant.
What is the ABUS symbol?
Overall, the evidence seems to point toward Moderna’s claims that its COVID-19 vaccine doesn’t use Arbutus-derived L NPs as being false. The other possibility is that Moderna attempted to modify the LNP system but only slightly so that potential identifiers, such as the molar ratio, remained the same. In this case, Arbutus could still claim that the LNPs currently in use by Moderna and in its COVID-19 vaccine infringe on their patent. It is also thus likely that the safety issues Moderna had acknowledged with this LNP system were largely unaffected if the potential modifications were indeed minor. Yet, if either of these scenarios is correct, the question becomes – Why wouldn’t Arbutus challenge Moderna once again to obtain royalty payments stemming from its COVID-19 vaccine?
When will Arbutus Biopharma release its earnings?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How much does Arbutus Biopharma make?
Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021. View our earnings forecast for Arbutus Biopharma.
What is the official website of Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $266.04 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63,740,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
Is Arbutus Biopharma a buy?
The official website for Arbutus Biopharma is www.arbutusbio.com.
Who is the CEO of Arbutus Biopharma?
Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Does Arbutus Biopharma pay dividends?
6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
How much did Arbutus stock lose in 2021?
Arbutus Biopharma does not currently pay a dividend.
What is Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation stock price ended on $2.71 on Monday after losing 1.81% (Updated on July 26, 2021) The Arbutus Biopharma Corporation stock price fell by -1.81% on the last day (Monday, 26th Jul 2021) from $2.76 to $2.71. and has now fallen 4 days in a row.
Is Arbutus Biopharma stock a negative stock?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically i... Read more
Where is Arbutus Biopharma headquartered?
We therefore hold a negative evaluation of this stock.
Does Abus pay dividends?
Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. More... Sector.
Is Arbutus Biopharma listed on the NASDAQ?
No, ABUS does not currently pay dividends. However, you can view Seeking Alpha’s hypothetical dividend projections here.
Arbutus Biopharma (ABUS)
Arbutus Biopharma Corporation is listed on the NASDAQ as (NASDAQ:ABUS).
Arbutus Biopharma Corporation - Buy
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Style Scorecard
Zacks' proprietary data indicates that Arbutus Biopharma Corporation is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ABUS shares relative to the market in the next few months.
Chart for ABUS
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
